Alpaca nanobodies show promising results in CAR-T solid tumor treatment

Scientists from Boston Children’s Hospital and Massachusetts Institute of Technology (MIT) have used alpaca-derived nanobodies to create a novel approach to CAR T cell therapy that addresses the challenge of treating patients with solid tumor cancers. Currently, CAR-T cell immunotherapy has been applied to the treatment of non-solid tumors such as acute lymphoblastic leukemia (ALL).

New Review Article Outlines Mechanisms of Resistance to CAR T Cell Therapy

Following successful clinical studies, the FDA and regulatory authorities around the world have approved the use of axicabtagene ciloleucel (Yescarta™) for patients with large-B-cell lymphomas and tisagenlecleucel (Kymriah™) for adults with certain types of non-Hodgkin lymphoma. Despite its success as a novel way of treating cancer, physician scientists are realizing that 30%-50% of patients who

Therapeutic peptides anchored to enveloped viruses boost T cell immunotherapy

Cancer can exploit immune regulatory checkpoints molecules by inhibiting anti-tumor immune responses from T cells. These immune checkpoint inhibitor (ICI) antibodies that activate anti-tumor immune responses can create durable responses in 10%–20% of cancer patients, but the remaining 80%–90% of the patients do not respond, driving the need to find novel combination therapies that increase

Presenting SUPRA CAR T cells – a split, universal, and programmable CAR system

T cells expressing chimeric antigen receptors (CAR T) are particularly promising for the treatment of refractory cancers. While Kymriah and Yescarta are FDA-approved for B-cell malignancies, safety and efficacy concerns remain across the cell therapy industry. Severe cytokine release syndrome triggered by T cell infusion is one of the urgent CAR T related downsides that needs

Synthetic IL-2 cytokine-receptor pairs enable selective targeting of engineered T cells

Interleukin-2 (IL-2) is a cytokine critical to effector T cell expansion, survival, and function. Importantly, IL-2 is supplemented in the production of T cells for immunotherapy, including CAR-T cell therapies. While IL-2 can improve T cell survival and efficacy, IL-2 provokes a wide range of responses by simultaneously activating and repressing different components of the